ImmunoGen logo

ImmunoGen

Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, aesthetics, and other areas of unmet need

34 employees · est. 1981

VS
Pyxis Oncology logo

Pyxis Oncology

Charting a course to therapeutics for difficult-to-treat cancer.

68 employees · est. 2019 · Boston, United States

ImmunoGen is the older company (1981 vs 2019); Pyxis Oncology is the larger of the two.

Side-by-Side Comparison

ImmunoGen Pyxis Oncology
Founded
1981 older 2019
Headquarters
Not tracked yet Boston, United States
Employees
34 68 larger
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Pharmaceutical
Funding Stage
Acquired Unknown
Total Funding
$681.30M $392.00M
Funding Rounds
11 4
Services
Drug Development, Clinical Trials Management, Cancer Research and Treatment Solutions, Healthcare Professional Support development of antibody-drug conjugates, immunotherapy research, clinical program management, oncology-focused drug development
Target Customers
Cancer Patients, Oncologists, Healthcare Providers, Research Institutions patients with difficult-to-treat cancers, healthcare professionals, oncologists, medical researchers
Taxonomy
Antibody-drug Conjugates, Cancer Treatment, Oncology, Immunology, Neuroscience, Therapeutics Development, Targeted Antibody Payload (TAP) Technology, Metastatic Breast Cancer, Hematological Malignancies, Solid Tumors, Collaboration Agreements, Licensing Partnerships Antibody-Drug Conjugates, Immunotherapy, Cancer Treatment, Biologics, Tumor Targeting, Immune Suppression Overcoming, Tumor Antigen-Specific TILs, Tumor-Infiltrating Lymphocytes, Cold Tumors, Hot Tumors, Tumor Cell Signaling, Antibody-Based Immunotherapies, Oncology Innovation, Therapeutic Development
Website
immunogen.com pyxisoncology.com
ImmunoGen logo

About ImmunoGen

ImmunoGen, Inc. is a biotechnology innovator, harnessing the potential of antibody-drug conjugates (ADCs) to revolutionize cancer treatment. With a focus on oncology, the company combines the precision of antibodies with the effectiveness of cytotoxic drugs, aiming to target cancer cells while spari...

Pyxis Oncology logo

About Pyxis Oncology

Pyxis Oncology, founded in 2019, is a biotech innovator based in the United States, focused on transformative cancer therapies. With a mission expressed through their slogan, "Charting a course to therapeutics for difficult-to-treat cancer," Pyxis aims to change the landscape of cancer treatment. T...

We will tell you when either one moves

BounceWatch watches ImmunoGen and Pyxis Oncology for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at ImmunoGen and Pyxis Oncology — by email.

Frequently Asked Questions

ImmunoGen — Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, aesthetics, and other areas of unmet need. Pyxis Oncology — Charting a course to therapeutics for difficult-to-treat cancer.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
ImmunoGen has raised $681.30M while Pyxis Oncology has raised $392.00M.
ImmunoGen and Pyxis Oncology operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare ImmunoGen with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at ImmunoGen on 10 Jun 2026, and Pyxis Oncology on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy